Browse Studies — Arctuva

Phase 3

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatm…

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2+ Breast Cancer

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT06876714

Phase 2

Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression

The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an eff…

Oligometastatic Breast CarcinomaBreast CancerMetastatic Breast Cancer+3 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05534438

Phase 1

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with…

Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more

Estimated

~$10 – $8,750

Phase 2

Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer: A Biomarker-Driven Pilot Clinical Trial

The goal of this clinical trial is to learn if alisertib in addition to usual care works to treat HR+/HER2+ breast cancer. The main questions it aims to answer…

HR+/HER2+ Breast CancerMetastatic Breast Cancer

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT07706179